B
BVF Partners L.P.
+ Con en carteraIMA
+8.72%
Rentabilidad a 3 meses
$4.105
-0.059 (-1.44%)Al cierre
Loading chart…
- Máximo
- 4.260
- Apertura
- 4.040
- Precio medio ponderado por volumen
- 4.14
- Volumen
- 1.40K
- Capitalización
- —
- Mínimo
- 4.040
- Importe
- 5.79K
- EV/EBITDA, TTM
- 0.00
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Análisis de IA of ImageneBio Inc (IMA)
MantenerImageneBio Inc is currently a hold. The stock is priced at $4.09, significantly below its 52-week high of $8.84, indicating potential upside. However, the company has reported a net loss of $10.6 million for Q1 2026 and has a negative forward P/E ratio of 0, which raises concerns about profitability. The RSI is at 46.487, suggesting it is neither overbought nor oversold, which aligns with a cautious approach.
Métricas de valoración
El PER previsto actual de ImageneBio Inc (IMA) es 0.00, frente a su media de 5 años de -2.20.
Ballenas con IMA en cartera
Cronología de eventos
Noticias
1.009-08NewsfilterImageneBio CEO to Participate in Investment Conference
- 5.008-17Newsfilter
ImageneBio Grants Stock Awards to New Employees
- 5.007-07Newsfilter
ImageneBio Appoints New General Counsel to Drive Growth
- 8.505-27Newsfilter
ImageneBio CEO to Present at Jefferies Global Healthcare Conference
9.505-08seekingalphaImageneBio Reports $10.6M Q1 Net Loss Amid $30M Financing
Preguntas frecuentes sobre IMA, respondidas por Alphio AI
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. It operates in the Healthcare sector.
ImageneBio Inc is currently a hold. The stock is priced at $4.09, significantly below its 52-week high of $8.84, indicating potential upside. However, the company has reported a net loss of $10.6 million for Q1 2026 and has a negative forward P/E ratio of 0, which raises concerns about profitability. The RSI is at 46.487, suggesting it is neither overbought nor oversold, which aligns with a cautious approach.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.